PMID- 31649887
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 9
DP  - 2019
TI  - Circulating Tumor Biomarkers in Meningiomas Reveal a Signature of Equilibrium 
      Between Tumor Growth and Immune Modulation.
PG  - 1031
LID - 10.3389/fonc.2019.01031 [doi]
LID - 1031
AB  - Meningiomas are primary central nervous system (CNS) tumors that originate from 
      the arachnoid cells of the meninges. Recurrence occurs in higher grade 
      meningiomas and a small subset of Grade I meningiomas with benign histology. 
      Currently, there are no established circulating tumor markers which can be used 
      for diagnostic and prognostic purposes in a non-invasive way for meningiomas. 
      Here, we aimed to identify potential biomarkers of meningioma in patient sera. 
      For this purpose, we collected preoperative (n = 30) serum samples from the 
      meningioma patients classified as Grade I (n = 23), Grade II (n = 4), or Grade 
      III (n = 3). We used a high-throughput, multiplex immunoassay cancer panel 
      comprising of 92 cancer-related protein biomarkers to explore the serum protein 
      profiles of meningioma patients. We detected 14 differentially expressed proteins 
      in the sera of the Grade I meningioma patients in comparison to the age- and 
      gender-matched control subjects (n = 12). Compared to the control group, Grade I 
      meningioma patients showed increased serum levels of amphiregulin (AREG), CCL24, 
      CD69, prolactin, EGF, HB-EGF, caspase-3, and decreased levels of VEGFD, TGF-alpha, 
      E-Selectin, BAFF, IL-12, CCL9, and GH. For validation studies, we utilized an 
      independent set of meningioma tumor tissue samples (Grade I, n = 20; Grade II, n 
      = 10; Grade III, n = 6), and found that the expressions of amphiregulin and 
      Caspase3 are significantly increased in all grades of meningiomas either at the 
      transcriptional or protein level, respectively. In contrast, the gene expression 
      of VEGF-D was significantly lower in Grade I meningioma tissue samples. Taken 
      together, our study identifies a meningioma-specific protein signature in blood 
      circulation of meningioma patients and highlights the importance of equilibrium 
      between tumor-promoting factors and anti-tumor immunity.
CI  - Copyright (c) 2019 Erkan, Strobel, Dorfer, Sonntagbauer, Weinhausel, Saydam and 
      Saydam.
FAU - Erkan, Erdogan Pekcan
AU  - Erkan EP
AD  - Research Program in Systems Oncology, Faculty of Medicine, University of 
      Helsinki, Helsinki, Finland.
FAU - Strobel, Thomas
AU  - Strobel T
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria.
FAU - Dorfer, Christian
AU  - Dorfer C
AD  - Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
FAU - Sonntagbauer, Markus
AU  - Sonntagbauer M
AD  - Austrian Institute of Technology, Molecular Diagnostics Center for Health and 
      Bioresources, Vienna, Austria.
FAU - Weinhausel, Andreas
AU  - Weinhausel A
AD  - Austrian Institute of Technology, Molecular Diagnostics Center for Health and 
      Bioresources, Vienna, Austria.
FAU - Saydam, Nurten
AU  - Saydam N
AD  - Department of Biochemistry, Molecular Biology, and Biophysics, Medical School, 
      University of Minnesota, Minneapolis, MN, United States.
FAU - Saydam, Okay
AU  - Saydam O
AD  - Division of Hematology and Oncology, Department of Pediatrics, Medical School, 
      University of Minnesota, Minneapolis, MN, United States.
LA  - eng
PT  - Journal Article
DEP - 20191010
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC6795693
OTO - NOTNLM
OT  - CNS tumors
OT  - biomarker
OT  - high-throughput immunoassay cancer panel
OT  - meningioma
OT  - proximity extension assay
OT  - serum biomarker
EDAT- 2019/10/28 06:00
MHDA- 2019/10/28 06:01
PMCR- 2019/01/01
CRDT- 2019/10/26 06:00
PHST- 2019/04/26 00:00 [received]
PHST- 2019/09/24 00:00 [accepted]
PHST- 2019/10/26 06:00 [entrez]
PHST- 2019/10/28 06:00 [pubmed]
PHST- 2019/10/28 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2019.01031 [doi]
PST - epublish
SO  - Front Oncol. 2019 Oct 10;9:1031. doi: 10.3389/fonc.2019.01031. eCollection 2019.